Bioprocessing Summit Europe Highlights Innovations in Gene Therapy CMC and Manufacturing
With the global market for gene therapy expected to hit $13 billion (USD) by 2024 (Research And Markets), Bioprocessing Summit Europe is returning March 24-26, 2020 with its popular Gene Therapy CMC and Manufacturing track.
Expanding to a new venue to accommodate increased registrations, the meeting will take place at The Crowne Plaza Barcelona (Spain)?Fira Center.
From the Plenary Keynote by Diane Blumenthal, PhD, Head, Technical Development, Spark Therapeutics, the first company to obtain approval of a gene-therapy product in the EU and US, to insights from Biogen, Sanofi, Vivet Therapeutics, Takeda and Ultragenyx, content will focus on accelerating therapies into the market.
"There is a real thirst for knowledge about how to rapidly deploy biologics while ensuring quality and cost-efficiency. This conference reveals the critical challenges facing the manufacture, analysis and control of these exciting new therapies," said Dan Barry, Senior Conference Director, CHI.
Among highlights:
A Keynote by James Warren, PhD, Vice President, Pharmaceutical Development, Ultragenyx, on Rapid CMC Development and Pre-Commercial Considerations for rAAV Gene Therapy Products for Rare Diseases
More than 15 sessions on Advancing CMC and Analytical Strategies, Optimizing Scale-Up and Process Control, and AAV Purification and Lentiviral Manufacturing
A short course on Quality Considerations for Gene Therapy Viral Vectors
The event will also include:
A Plenary Keynote by Ralf Schumacher, PhD, Global Head, Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG
130+ presentations on Upstream Processing, Downstream Processing, Analytical and Formulation, Cell Therapy CMC and Manufacturing, and the Gene Therapy content
About Cambridge Healthtech Institute
Cambridge Healthtech Institute (CHI), a division of Cambridge Innovation Institute, is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech, CROs, academia, and niche service providers. CHI is renowned for its vast conference portfolio held worldwide including PepTalk, Molecular Medicine Tri-Conference, SCOPE Summit, Bio-IT World Conference & Expo, PEGS Summit, Drug Discovery Chemistry, Biomarker World Congress, World Pharma Week, The Bioprocessing Summit, Next Generation Dx Summit, Immuno-Oncology Summit, and Discovery on Target. CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Bio-IT World, Clinical Research News and Diagnostics World.
The "Global Proteomic Biomarker Analytics Market Forecasts by Application, Technology, Product, and Place, with Executive & Consultant Guides; Including Customized Forecasting and Analysis" report has been added to ResearchAndMarkets.com's offering....
The "Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and by Country. With Market Analysis and Executive Guides. 2024 to 2028" report has been added to...
IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, today announced that China National Medical Products Administration (NMPA) has approved the...
The "Flow Cytometry Markets. Forecasts by Technology, Product and Application. With Executive and Consultant Guides. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering.
The technology is moving faster than the market. Find the...
The "Immunoassay Markets. Strategies and Trends. Forecasts by Application, Technology, Product, User and by Country. With Executive Guides, Customized Forecasting and Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering....